Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Dividend investors seeking a stable healthcare investment may find themselves weighing two companies: Johnson & Johnson (JNJ) and Kenvue (KVUE). Both have a long track record of increasing dividends, with JNJ marking its 64th consecutive increase and KVUE being part of that lineage. However, there are key differences that could influence a buy-and-hold strategy.

JNJ, now a pure-play pharmaceutical and medical technology firm after spinning off its consumer health division, focuses on higher-growth areas like oncology and surgical devices. Despite a $3.7 billion reserve for talc-related liabilities, JNJ remains a reliable dividend payer with a modest forward yield of 2%. Analysts generally rate JNJ as a "Moderate Buy," with a target price of $320.

In contrast, KVUE, with a much higher forward yield of 4.71%, appears more attractive on paper. However, its growth prospects appear limited as it owns mature consumer staple brands slated for acquisition by Kimberly-Clark. The proposed acquisition valuation at $48.7 billion casts uncertainty on KVUE's future financials and dividend stability. Analysts rate KVUE as a "Hold" with a mean target price of $19.

In conclusion, while KVUE offers a higher yield, JNJ's more diversified business model, growing focus on higher-risk/higher-margin areas, and lower legal liability exposure make it the stronger buy-and-hold choice for dividend investors.